Eledon Pharmaceuticals Reports $70.7 Million Net Loss for Six Months Ended June 30, 2026

Eledon Pharmaceuticals, Inc. reported a significant net loss of $70.7 million for the six months ended June 30, 2026, compared to a loss of $17.7 million for the same period in 2025. The company's total operating expenses increased to $44.1 million from $42.7 million year-over-year, driven primarily by a rise in research and development costs, which totaled $35.4 million, up from $33.8 million. The increase in R&D expenses was largely attributed to higher manufacturing costs and personnel-related expenses, despite a decrease in costs associated with the kidney transplantation programs. The company’s cash and cash equivalents, along with short-term investments, stood at $88.8 million as of June 30, 2026, down from $135.7 million at the end of 2025.

In terms of operational developments, Eledon has been focusing on its lead compound, tegoprubart, which is in clinical trials for preventing organ rejection in kidney transplants and treating amyotrophic lateral sclerosis (ALS). The company has made strategic decisions to prioritize its kidney transplantation programs, which are seen as critical given the high demand for kidney transplants in the U.S. Eledon has received regulatory approvals for a Phase 1b clinical trial and a Phase 2 trial, with the first subject in the Phase 2 BESTOW trial dosed in August 2023. The company is also planning to initiate a Phase 3 clinical trial for tegoprubart in late 2026, contingent on securing additional financing.

Eledon's financial position reflects a substantial accumulated deficit of $471.9 million as of June 30, 2026, indicating the ongoing challenges the company faces in achieving profitability. The company has indicated that it will need to seek additional capital through various means, including public or private equity offerings, to fund its operations and clinical development plans. The management has expressed concerns about the company's ability to continue as a going concern without securing further financing, given the current cash flow situation and the anticipated costs associated with advancing its clinical programs.

The company’s stockholder equity decreased to $33.0 million from $81.1 million at the end of 2025, primarily due to the net losses incurred during the period. Eledon has also seen fluctuations in its warrant liabilities, which increased to $40.0 million as of June 30, 2026, reflecting changes in the fair value of its common stock. The company’s strategic focus on immunology and the CD40L pathway positions it for potential growth, but the need for additional funding remains a critical factor in its future operations and development efforts.